 |
贺耘，教授，美国顶级生物医学研究所（斯克利普斯研究所）博士，硕博导师,1965年生。1990年毕业于香港中文大学，获硕士学位。1992年，毕业于美国爱荷华州立大学，获硕士学位。2000年，获美国斯克利普斯研究所博士学位。 在国际500强制药企业公司雅培,诺华及罗氏，美国生物科技公司(ISIS)和国际知名医药外包公司（PPD）具有超过15年从事药物研发经验，成功组建并管理多个研发团队，团队成员达500余人，领导参与30余项创新药物研发项目，为创新药物开发成功贡献了8个临床药物（1.1类新药, I, II和III期）及10余个临床前药物。在战略规划、投资组合、团队建设、项目管理和科学研究方面具有极强的综合素质，在工业界和学术界具有广泛的联系。作为发明人申请专利70项, 35项专利获美国授权，在世界一流学术等期刊上发表论文59篇。曾任中美生物技术与制药协会会长，现为百华协会理事，北京大学及中国科学院上海药物所访问教授。 |
研究方向
有机化学、生物化学、药物化学方向：
1. 药物设计与合成
2. 活性天然产物的全合成与结构修饰
代表性论文、专著和专利
[1] G. Zhang, P. Ren, N.S. Gray, T. Sim, X. Wang, Y. Liu, J. Che, W. Dong, S.S. Tian, M.L. Sandberg, T.A. Spalding, R. Romeo, M. Iskandar, Z. Wang, M.H. Seidel, D.S. Karanewsky, Y. He, “Discovery Of Pyrimidine Benzimidazoles as Src-family Selective Lck Inhibitors. Part II.” Bioorg. Med. Chem. Lett. 2009, 19, 6691.
[2] S. Huang, Z. Liu, S.-S. Tian, M. Sandberg, T.A. Spalding, R. Romeo, M. Iskandar, Z. Wang, D.S. Karanewsky, Y. He, “Discovery Of 2-Amino-6-Carboxamidobenzothiazoles As Potent Lck Inhibitors.” Bioorg. Med. Chem. Lett.2008, 18, 2324-2328.
[3] G. Zhang, P. Ren, N.S. Gray, T. Sim, Y. Liu, X. Wang, J. Che, S.-S. Tian, M.L. Sandberg, T.A. Spalding, R. Romeo, M. Iskandar, D. Chow H.M; Seidel, D.S. Karanewsky, Y. He, “Discovery Of Pyrimidine Benzimidazoles As Lck Inhibitors: Part I.”Bioorg. Med. Chem. Lett.2008, 18, 5618-5621.
[4] T.H. Marsilje, P.B. Alper, W. Lu, D. Mutnick, P.-Y. Michellys, Y. He, D.S. Karanewsky, D. Chow, A. Gerken, J. Lao, M.-J. Kim, H.M Seidel, H. Martin; S.-S. Tian, “Optimization Of Small Molecule Agonists Of The Thrombopoietin (TPO) Receptor Derived From A Benzo[A]Carbazole Hit Scaffold.” Bioorg. Med. Chem. Lett. 2008, 18, 5259-5262.
[5] P.B. Alper, T.H. Marsilje, D. Mutnick, W. Lu, A. Chatterjee, M.J. Roberts, Y. He, D.S. Karanewsky, D. Chow, J. Lao, A. Gerken, T. Tuntland, B. Liu, J. Chang, P. Gordon, H. M. Seidel, S.-H. Tian, “Discovery And Biological Evaluation Of Benzo[A]Carbazole-Based Small Molecule Agonists Of The Thrombopoietin (TPO) Receptor.” Bioorg. Med. Chem. Lett.2008, 18, 5255-5258.
[6] V. R. Gadhachanda, B. Wu, Z. Wang, K. L. Kuhen, J. Caldwell, H. Zondler, H. Walter, M. Havenhandb, Y. He, "4-Aminopyrimidines As Novel HIV-1 Inhibitors." Bioorg. Med. Chem. Lett., 2006, 16, 260-265.
[7] S. F. Yan, F. J. King, Y. He, J. S. Caldwell, Y. Zhou, “Learning from the Data: Mining of Large High-Throughput Screening Databases.”J. Chemical Information and Modeling 2006, 46, 2381-2395.
[8] Z. Wang, B. Wu, K. L. Kuhen, B. Bursulaya, D. G. Nguyen, Y. He, "Synthesis and biological evaluations of terephthalamates as novel HIV-1 integrase inhibitors."Bioorg. Med. Chem. Lett., 2006, 16, 4174-4177.
[9] D. Ellis, K. L. Kuhen, B. Anaclerio, B. Wu, K. Wolff, H. Yin, B. Bursulaya, J. Caldwell, D. Karanewsky, Y. He, "Design, Synthesis And Biological Evaluations Of Novel Quinolones As HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors." Bioorg. Med. Chem. Lett. 2006, 16, 4246-4251.
[10] Z. Wang, B. Wu, K. L. Kuhen, B. Bursulaya, T. N. Nguyen, D. G. Nguyen, Y. He, "Synthesis And Biological Evaluations Of Sulfanyltriazoles As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors." Bioorg. Med. Chem. Lett. 2006, 16, 4174-4177.
[11] B. Wu, K. Kuhen, T. N. Nguyen, D. Ellis, B. Anaclerio, X. He, K. Yang, D. Karanewsky, H. Yin, K. Wolff, K. Bieza, J. Caldwell, Y. He, "Synthesis and Evaluation of N-Aryl Pyrrolidinones as Novel Anti-HIV-1 Agents. Part 1" Bioorg. Med. Chem. Lett. 2006, 16, 3430-3433.
